Correction to: Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy.

Clin Transl Oncol

Laboratory of Hematology-Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Published: April 2020

Acknowledgements section was missing.

Download full-text PDF	Source
http://dx.doi.org/10.1007/s12094-019-02198-5	DOI Listing

Publication Analysis

correction gr-mdsc-linked

gr-mdsc-linked asset

asset potential

potential immune

immune biomarker

biomarker pretreated

pretreated nsclc

nsclc receiving

receiving nivolumab

nivolumab second-line

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!